Status:
COMPLETED
Induction of HO-1; a Therapeutic Approach to Reduce Ischaemia Reperfusion Injury (IRI) Following Deceased Donor Renal Transplantation
Lead Sponsor:
University of Edinburgh
Collaborating Sponsors:
NHS Lothian
Conditions:
Graft Failure
Ischemia-reperfusion Injury
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a blinded, placebo-controlled, randomised controlled trial looking at the effects of Heme arginate (HA) on cadaveric renal transplantation. The investigators know that HA can upregulate HO-1, ...
Detailed Description
Patients will be recruited from the East of Scotland transplant waiting list and consent when they arrive in the hospital. The investigators will randomise them to drug or placebo and give the infusio...
Eligibility Criteria
Inclusion
- all patients receiving a cadaveric single kidney transplant
- patients on a standard immunosuppressive regime
Exclusion
- patients on different immunosuppressives
- patients receiving 3rd or subsequent kidney transplant
- patients are fully anti-coagulated
- patients unable to take Heme Arginate
- patients unable to give informed consent
- patients on combined anti-platelet agents
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01430156
Start Date
January 1 2012
End Date
August 1 2013
Last Update
May 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Infirmary of Edinburgh/ University of Edinburgh
Edinburgh, Lothian, United Kingdom, EH16 4TJ